During last week’s 22nd Annual Meeting of the Chinese Society of Clinical Oncology, held from September 18-22 in Xiamen, China, drug maker Innovent Biologics presented updated results for its proposed bevacizumab biosimilar, IBI305, in an oral session.
During last week’s 22nd Annual Meeting of the Chinese Society of Clinical Oncology, held from September 18-22 in Xiamen, China, drug maker Innovent Biologics presented updated results for its proposed bevacizumab biosimilar, IBI305, in an oral session.
IBI305, which is being investigated as a biosimilar to the reference Avastin, is being studied in the randomized, double-blind, phase 3 clinical trial CTR20160848.
In the study, patients with advanced non—small cell lung cancer were randomized to receive either the proposed biosimilar (n = 244) or the reference bevacizumab (n = 226), plus paclitaxel/carboplatin. By the cut-off date of March 31, 2019, the independent radiology review committee–assessed overall response rates were 47.1% in the biosimilar arm and 46.8% in the reference arm.
By May 22, 2019, investigator-evaluated median progression-free survival in the biosimilar arm and the reference arm were 7.3 months and 7.5 months, respectively, with no statistically significant difference (P = .893).
The biosimilar has also been studied in a randomized, double-blind, parallel, positive-controlled single-dose study, compared the pharmacokinetic profile, safety, tolerability, and immunogenicity of the biosimilar and the reference in 100 healthy volunteers. Innovent earlier said that this study met its primary end point of demonstrating similar pharmacokinetic profiles between the 2 drugs.
“We hope this drug can be launched on the market soon and provide more treatment options to patients," said Li Zhang, MD, Cancer Prevention and Treatment Center, Sun Yat-sen University, Guangzhou, Guangdong, China, in a statement announcing the results of the trial.
Hui Zhou, PhD, vice president and head of oncology strategy and medical sciences at Innovent, added that "Lung cancer is the malignant [tumor] with the highest morbidity and mortality in China. Currently, we have [8] registration trials in progress, [4] of which are for the treatment of lung cancer. We hope to bring more clinical benefits to patients through our efforts and address the significant unmet medical needs in China.”
Currently, Innovent is awaiting a regulatory decision from China’s National Medical Products Administration, which accepted for review a new drug application for the biosimilar in January of this year. The biosimilar is being evaluated under a priority review status. Also being reviewed by Chinese regulators is Innovent’s proposed biosimilar rituximab, IBI301.
The Trump Administration’s Drug Price Actions and Why US Prices Are Already Sky-High
May 17th 2025While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more complex web of development costs, profit incentives, and absent price controls—raising the question of whether any single policy, including potential drug tariffs, can truly untangle it.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.